IBA Business Update – First Quarter 2022
19 Mai 2022 - 07:00AM
IBA Business Update – First Quarter 2022
Louvain-La-Neuve, Belgium, 19 May
2022 - IBA (Ion Beam Applications S.A., EURONEXT), the
world leader in particle accelerator technology, today announces
its business update for the first quarter ending 31 March 2022.
Group Overview
- Strong balance sheet maintained with EUR 113 million net cash
position
- Business operations continue to be solid, with good performance
across all business units
- Backlog remains high at EUR 1.2 billion and new tenders
continue to progress internationally with active discussions
ongoing
- Solid order intake with one Proteus®ONE1 and three Other
Accelerators systems sold in the period with nine additional Other
Accelerators systems sold and the first proton therapy order
received from CGN Medical Technologies post-period end
- Expansion of Dosimetry offering with the acquisition of quality
assurance (QA) company, Modus Medical Devices, post-period end
Olivier Legrain, Chief Executive Officer
of IBA commented: “IBA’s strong performance has continued
into the first quarter of 2022, with good momentum across all
business lines on an international scale. Against the backdrop of
ongoing global economic and geopolitical challenges, our active
pipeline, increasing recurring revenue stream and excellent balance
sheet ensure that we are in a robust position to weather any
uncertainty.”
Proton Therapy
- 23 projects ongoing, with eight Proteus®PLUS2 and 15
Proteus®ONE systems in progress
- Strong pipeline continues across all geographies
- One new service contract in the quarter and a further
post-period, with a total of 41 service contracts now generating
recurring revenues globally
- One Proteus®ONE proton therapy solution contract signed
- Partnership with global engineering company, Tractebel, to
support IBA’s customers with proton therapy design and construction
projects
- Post-period end, IBA received its first order from CGN Medical
Technologies for a Proteus®PLUS proton therapy system to be
installed in Yangzhou, China
- Research collaboration with University Medical Center Groningen
(UMCG) for the development of a new FLASH irradiation protocol for
the treatment of early-stage breast cancer
- Ongoing expansion of Campus, the world’s first online proton
therapy platform
Other Accelerators (RadioPharma,
Industrial)
- Other Accelerators continued to perform strongly in the first
quarter with three systems sold in the period and an additional
nine sold post-period end
- Launch of a new low energy compact cyclotron, the Cyclone® KEY,
improving access to diagnosis solutions in emerging market
countries with in-house isotope production in hospitals
- Increasing demand for Rhodotron® for medical sterilization,
with this part of the business performing particularly well
Dosimetry
- Very strong order intake with backlog remaining at a record
high
- Collaborative agreement with Elekta to optimize quality
assurance (QA) solutions of radiation therapy departments and
clinics using Elekta’s treatment delivery systems
- Acquisition of Modus Medical Devices, specializing in phantoms
for QA for radiation therapy, expanding the business unit’s service
offering
Outlook IBA has continued to
perform well across all business lines in the first quarter of
2022. Our pipeline remains highly active, particularly in the US
and Asia, and, coupled with our growing recurring revenue stream,
provides significant visibility on future sales. Alongside this,
our balance sheet remains very strong, giving us optionality to
support long-term growth.
We have seen a modest impact from the ongoing
conflict in Ukraine and its effect on the global supply chain and
transportation. Although it is difficult to predict the impact of
the conflict on IBA’s performance for the rest of the year, the
associated disruptions and delays are currently manageable and we
continue to work to monitor and mitigate our risks.
Financial calendar Half year
Results
31 August 2022Business Update Q3
2022
17 November 2022
About IBAIBA (Ion Beam
Applications S.A.) is the world leader in particle accelerator
technology. The company is the leading supplier of equipment and
services in the field of proton therapy, considered to be the most
advanced form of radiation therapy available today. IBA is also a
leading player in the fields of industrial sterilization,
radiopharmaceuticals and dosimetry. The company, based in
Louvain-la-Neuve, Belgium, employs approximately 1,600 people
worldwide. IBA is a certified B Corporation (B Corp) meeting the
highest standards of verified social and environmental
performance.
IBA is listed on the pan-European stock exchange
EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at:
www.iba-worldwide.com
For further information, please
contact:
IBASoumya ChandramouliChief
Financial Officer+32 10 475 890Investorrelations@iba-group.com
Olivier LechienCorporate Communication
Director+32 10 475 890communication@iba-group.com
For media and investor enquiries: Consilium
Strategic Communications Amber Fennell, Angela Gray, Lucy
Featherstone +44 (0) 20 3709 5700 IBA@consilium-comms.com
1 Proteus®ONE is a brand name of Proteus®235
2 Proteus®PLUS is a brand name of Proteus®235
- 220519-IBA-Q1-Business-Update-EN
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024